· Univest Securities retained for proposed financing & uplist to national stock exchange
· Company to present at today’s Emerging Growth Conference at 2:30 PM EDT
New York, NY, and Tel Aviv, ISRAEL - 
(NewMediaWire) - September 15, 2021 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into an agreement with holders of the Company’s convertible notes that provides for a 90-day moratorium on conversions and a 90-day prohibition on sales of common shares by those noteholders issued as a result of conversion notices submitted after September 1st, 2021 (collectively the “Lockup”).
Additionally, the Company has retained the services of Univest Securities for a proposed underwritten public offering of securities that is expected to be completed in conjunction with a listing of the Company’s common shares on a national stock exchange.
“We are very pleased to have received the support from our existing convertible note holders with this lockup agreement,” said Gerald E. Commissiong, President & CEO. “We have recently seen a significant increase in interest in the Company from individual and institutional investors as a result of significant advancements we have made in terms of our COVID related test offering at our highly automated CLIA/CAP lab Provista Diagnostics based in the Atlanta area. Moving forward, we expect even greater interest in our programs from the investment community as we make progress with our clinical-stage Tollovir® oral antiviral 3CL protease inhibitor therapeutic programs for both hospitalized and non-hospitalized patients, as well as our Tollotest™ companion biomarker that measures 3CL protease activity. We expect to release results later this quarter from an observational study Phase 1/2 study of Tollovir that was conducted in Israel in 2020, provide updates on the ongoing randomized, double-blind, placebo-controlled Phase 2 clinical trial in hospitalized COVID patients for Tollovir currently enrolling in Israel, as well as provide updates on the initiation of Phase 2/3 clinical trials planned for Tollovir in both hospitalized and non-hospitalized patients. We believe this lockup agreement will provide confidence to the marketplace, give the Company sufficient room to complete certain strategic transactions currently being evaluated to unlock shareholder value and help facilitate the listing of our common shares on a national stock exchange in the months ahead.”
Todos will be presenting at today’s Emerging Growth Conference at 2:30 PM. To register please click on: https://goto.webcasts.com/starthere.jsp?ei=1487778&tp_key=ec487e0e97&sti=twitter
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 20201, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos is focused on the commercialization of Videssa and will bring the TBIA tests to market thereafter.
Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to address the COVID-19 pandemic. The Joint-Venture is pursuing the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s proprietary therapeutic candidate Tollovir™ is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to initiate Phase 2/3 clinical trials for both hospitalized and non-hospitalized patients in Israel.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos is also distributing certain (COVID-19) testing materials and supplies to CLIA-certified labs in the United States. The products cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
